Deerfield Management Company L.P. Series C Has $21.50 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Deerfield Management Company L.P. Series C lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 0.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,497,000 shares of the company’s stock after selling 11,943 shares during the period. Deerfield Management Company L.P. Series C’s holdings in 10x Genomics were worth $21,497,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in TXG. Signaturefd LLC boosted its stake in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in 10x Genomics during the fourth quarter worth about $52,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after acquiring an additional 4,324 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

Shares of TXG opened at $8.31 on Thursday. The firm has a 50-day moving average of $9.00 and a 200-day moving average of $12.67. The company has a market cap of $1.02 billion, a PE ratio of -5.47 and a beta of 1.94. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $28.25.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Barclays decreased their price target on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Finally, Stifel Nicolaus reduced their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus target price of $18.85.

Insider Buying and Selling

In other news, Director Alan Mateo acquired 40,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were purchased at an average cost of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares in the company, valued at $687,237.74. This represents a 184.41 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the sale, the insider now directly owns 335,324 shares of the company’s stock, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.